The immunogenicity of a polyvalent HIV-1 vaccine comprised of Env antigens from primary R5 isolates was evaluated in rhesus macaques. DNA vaccines encoding four Env antigens from multiple HIV-1 subtypes and HIV-1 Gag antigen from a single subtype elicited a persistent level of binding antibodies to gp120 from multiple HIV-1 isolates that were markedly enhanced following boosting with homologous gp120 proteins in QS-21 adjuvant irrespective of the route of DNA immunization. These sera neutralized homologous and, to a lesser degree, heterologous HIV-1 isolates. Four of the six immunized animals were completely protected following rectal challenge with a SHIV encoding Env from HIV-1 Ba-L , whereas the virus load was reduced in the remaining animals compared to naïve controls. Hence priming with DNA encoding Env antigens from multiple HIV-1 clades followed by boosting with homologous Env proteins elicits anti-HIV-1 immune responses capable of protecting macaques against mucosal transmission of R5 tropic SHIV isolate.
Introduction
Despite an intensive global effort to control human immunodeficiency virus type 1 (HIV-1) infection, more than 40 million people are infected globally, and it is estimated that nearly 16,000 people are newly infected with the virus daily. A highly active anti-retroviral therapy (HAART) has been proven to be effective in controlling viral load in infected individuals (Mocroft et al., 2003a) . However, such therapies are expensive, cause serious side effects, and may eventually lead to viral resistance (Fatkenheuer et al., 1997; Mocroft et al., 2003b; Shelburne et al., 2005; Wit et al., 1999) . A prophylactic vaccine, effective in various regions of the world, is desperately needed to thwart this pandemic. This is especially true in developing nations where the infection is spreading at an alarming rate and opportunities for drug interventions are limited. Development of a broadly effective vaccine has become a major challenge since specific subtypes of HIV-1 are prevalent in various regions of the world and often these subtypes are quite divergent Nabel, 2001; Nabel et al., 2002) . Virology 348 (2006) 341 -353 www.elsevier.com/locate/yviro Since high-titered neutralizing antibodies as well as a broad cellular immunity are inversely correlated with HIV-1 disease progression in humans (Pantaleo and Fauci, 1996; Soudeyns and Pantaleo, 1999) , it was proposed that a prophylactic HIV-1 vaccine should elicit both humoral and cell-mediated immune (CMI) responses for the containment of viral infection (Letvin, 1998 (Letvin, , 2005 Mascola and Nabel, 2001) . Although DNA vaccines prime both humoral and cellular immune responses, the levels are often quite low in nonhuman primates or humans (Calarota and Weiner, 2004; Estcourt et al., 2004; Robinson, 1999) . Hence, efforts have been directed towards boosting such immune responses by combining DNA vaccines with different vaccination modalities in the boosting phase. Indeed, several preclinical studies have clearly demonstrated significant control of plasma viremia against pathogenic SHIV challenge using prime-boost vaccines, which contained a DNA prime component, and the boosting agents are often live vector-based vaccines directed primarily at eliciting CMI responses (Amara et al., 2001; Barouch et al., 2000; Doria-Rose et al., 2003; Shiver et al., 2002) .
Passive immunization experiments have demonstrated the protective effects of HIV-1 Env-specific neutralizing antibodies against SHIV transmission (Gauduin et al., 1997; Lewis et al., 1993; Mascola et al., 1999 Mascola et al., , 2000 Shibata et al., 1999) . Therefore, several vaccines have been designed to use Envbased immunogens in an effort to protect macaques from SHIV and SIV challenge (Amara et al., 2002; Letvin et al., 2004) . It was demonstrated previously that anti-Env antibody responses were broadened significantly following immunization with a cocktail of Env proteins in vaccinia-primed macaques (Cho et al., 2001) . Polyvalent Env vaccines representing Env antigens from different subtypes of HIV-1, which are currently circulating globally, have not been extensively evaluated. Further, it is not clear whether the number of immunogens in a polyvalent Env vaccine influences the overall immune response of the vaccine. A recent study has demonstrated that immunization of macaques with DNA prime/recombinant adenovirus boost vaccines encoding Env from clades A, B, and C was able to elicit broad Env-specific T lymphocyte and antibody responses (Seaman et al., 2005) .
Generally, DNA vaccines are effective in stimulating cellular immune responses (Amara et al., 2001; Barouch et al., 2000; Robinson, 1999) , while subunit proteins are more effective in eliciting antibody responses (Clements-Mann et al., 1998; Earl et al., 2001 Earl et al., , 2002 Graham et al., 1993) . Env vaccines in the form of subunit Env protein have been shown to be safe and effective in eliciting antibody response in the immunized hosts. It has been previously demonstrated that high-titered Env-specific antibody responses could be elicited with limited Env protein boosts in hosts primed with Env-expressing DNA vaccines (Barnett et al., 1997; Cherpelis et al., 2001b; Leung et al., 2004; Richmond et al., 1997) . In the current study, a similar DNA prime and Env protein boost vaccination regimen was evaluated in the nonhuman primate model as the first step to establish the immunogenicity of this vaccination approach in delivering polyvalent HIV formulations. Rhesus macaques were initially immunized with DNA vaccines encoding env genes (gp120) from multiple clades of HIV-1 of R5 phenotype. Results presented here clearly demonstrate that boosting of DNAprimed macaques with gp120 proteins was highly effective in eliciting significantly high-titered anti-Env antibody responses recognizing a wide range of primary Env antigens. The immune sera neutralized T cell line adapted (TCLA) and primary HIV-1 isolates with a varying degree of efficiency. Mucosal challenge of these immunized animals with an R5 SHIV isolate led to complete protection in the majority of immunized animals and a significant containment of plasma viremia in the remaining immunized animals compared to naïve animals.
Results

Immunization schedule
The immunization regimen of this study, consisting of both primary and secondary immunization phases, is shown in Fig. 1 . The polyvalent DNA vaccines encoded the env gene from four primary HIV-1 isolates: 92US715.6 (clade B), Ba-L (clade B), 96ZM651 (clade C), and 93TH976.17 (clade E) and the gag gene from a molecularly cloned virus NL4-3 (clade B). Three animals (961L, 963L, 969L) received DNA vaccines by gene Fig. 1 . Immunization schedule. Six macaques were divided into two groups. Three animals were immunized with polyvalent DNA by gene gun and the other three by ID route. All animals received protein immunization intramuscularly. Animals in both studies were challenged with SHIV-Ba-L by rectal route. Arrows indicate times of vaccination. gun and three animals (971L, 974L, 975L) were immunized with the same polyvalent DNA immunogens by ID route on weeks 0, 6, 14, and 18. Animals were boosted with four homologous gp120 proteins in QS-21 adjuvant by IM route on weeks 24 and 32. After confirmation of both antibody and cellmediated immune responses from this primary immunization regimen, a secondary phase of immunization was given with DNA on week 110 and protein on weeks 115 and 132 to evaluate the longevity of HIV-1-specific antibody responses in immunized animals. In order to determine whether boosting with Gag protein would enhance CMI response to HIV-1 Gag antigen, animals were also immunized with HIV-1 (HXB2) Gag p41 protein on week 58 (not shown in Fig. 1 ). Animals were challenged with SHIV-Ba-L via rectal route on week 135. Seven naïve macaques were also challenged with the same dose of SHIV-Ba-L via rectal route.
Antibody response elicited by the DNA prime and protein boost vaccine during primary immunization phase
Serum antibody titers to individual gp120 and p41 Gag proteins were assayed by ELISA following four DNA and two protein immunizations (Fig. 2) . Antibody titers measured after the first DNA immunization were very low (data not shown). However, the titers against each gp120 increased steadily with subsequent DNA immunizations (Fig. 2 ). Immunization of DNA using gene gun consistently elicited nearly two logs higher antibody titers against each of the four primary gp120 Fig. 2 . Antibody titers to Env and Gag proteins in macaques immunized with polyvalent DNA and gp120 proteins during the primary immunization phase. Antibody titers in the serum of macaques vaccinated with DNA by either gene gun (closed symbol) or ID route (open symbol) and gp120 proteins by IM route were assayed by ELISA against gp120 protein from primary HIV-1 isolates 92US715.6 (clade B), Ba-L, 96ZM651 (clade C), and 93TH976.17 (clade E) or against HXB2 Gag protein. Serum was collected 2 weeks after each immunization. Antibody titers are based on the dilution of immune serum producing two times the optical density at 450 nm compared with the corresponding dilution of preimmune serum and are expressed as the mean antibody titer ± SEM from three macaques of either gene gun or ID immunized group. antigens (between 1:1000 and 1:10,000) as compared to the ID route (between 1:10 and 1:100). This enhanced response was observed against each gp120 protein (Fig. 2) . Boosting of DNA-primed animals with a single administration of polyvalent gp120 proteins enhanced antibody titers markedly. The gene gun group had a slightly higher titer than the ID group, especially against three of the four gp120 proteins present in the immunogens (Fig. 2 ). However, after two protein boosts, all the animals had Env-specific antibody titers above 1:100,000, and titers were comparable in all animals irrespective of the route of DNA priming ( Figs. 2A-D) . Similarly, antibodies to Gag protein were also detected after DNA administration, especially in the gene gun immunized animals. Moreover, titers were lower than anti-gp120 antibodies and declined slightly after the gp120 protein boost, as Gag protein was not administered to the animals (Fig. 2) .
In order to determine whether antibodies elicited by the multivalent DNA prime/protein boost vaccine are functional, sera collected 2 weeks after the fourth DNA immunization and each protein boost were assayed for neutralization of a number of HIV-1 isolates from multiple clades ( Fig. 3 ). Different assays were performed to examine multiple aspects of HIV-1 neutralization by the immune sera. These assays examined neutralization of a number of HIV-1 isolates both homologous and heterologous to the vaccine strains and were conducted independently in different laboratories with cell-free virus. Since HIV-1 also propagates via cell-to-cell transfer, we examined neutralization of cell-to-cell transmission of virus by syncytium assay. In this assay, we quantitated inhibition of syncytium formation induced by coculturing HIV-1 infected cells with uninfected target cells in the presence of immune sera. Initially, we tested neutralization of three isolates (SHIV-Ba-L, 92US715.6, and 96ZM651) homologous to the vaccine. Neutralization of 92US715.6 and 96ZM651 was examined by cell-cell transmission assay, and neutralization of SHIV-Ba-L was examined with cell-free virus in U373 cells. DNA immunization elicited weak neutralizing activity in four out of six animals against 92US715.6 and two out of six animals against 96ZM651 but failed to elicit measurable neutralization titers against SHIV-Ba-L at the lowest dilution of serum (1:4) tested ( Fig. 3A ). However, sera after each protein boost neutralized these isolates markedly with higher titers observed after the second boost ( Fig. 3A ). Neutralization of several heterologous primary isolates across HIV-1 subtypes A, B, C, and E was also tested using these sera ( Fig. 3B ). As observed with homologous isolates, none of the primary isolates were neutralized after DNA immunization. However, a clade A (DJ263) and a number of clade B isolates were neutralized after the first protein boost, and the percent neutralization was increased following the second protein boost (Fig. 3B ). Since two protein boosts were necessary to elicit neutralizing antibody responses against a number of isolates, serum from each animal Fig. 3 . Neutralizing activity in the serum of rhesus macaques following DNA prime/protein boost immunization. Sera were collected 2 weeks after four DNA and two protein immunizations and tested for neutralization of HIV-1 isolates. (A) Neutralization of SHIV-Ba-L was conducted with cell-free virus in U373 cells and of B715 (92US715.6) and Czm (96ZM651) by cell-cell transmission assay as described in Materials and methods. Neutralization titers are expressed as dilution of immune sera inhibiting 50% of viral infection ± SEM from six immunized macaques. The minimum dilution of serum tested in each assay was 1:4. (B) Sera were tested for neutralization at a 1:5 dilution for inhibitory activity against panels of HIV-1 isolates from clades A, B, C, and E by flow cytometric assay as described in Materials and methods. Data are presented as the mean percent inhibition of infection ± SEM from six immunized macaques. after two protein boosts was tested for neutralization of a number of HIV-1 clade B isolates, and the results are shown in Table 1 . Although HIV-1 MN and two primary isolates (Ba-L and SF162) were neutralized by the most of the immune sera, other isolates were not neutralized in this assay.
HIV-1 Gag-specific cellular immune responses in immunized macaques
HIV-1 Gag antigen was included in the DNA vaccine phase of this polyvalent DNA prime/protein boost vaccine since it has been demonstrated that immunogens based on HIV-1 Gag alone were able to control plasma viremia in challenged macaques (Shiver et al., 2002) . Inclusion of a Gag antigen as part of the DNA priming would increase the breadth of immune responses elicited by an Env-based DNA prime plus protein boost strategy. It was of interest to determine whether Gag-specific CMI response following DNA immunization would be elicited in such a formulation without interference from Env DNA vaccines. PBMC from immunized macaques were isolated at 2 weeks after the fourth DNA immunization, and the Gag-specific T cells were measured by IFN-γ ELISPOT assay, using HIV-1 MN Gag peptide pools spanning the p55 protein (15-mers with 11 amino acid overlap, 12 peptides in each pool). As shown in Fig. 4 , two of three animals in each gene gun or ID group exhibited positive responses against one or more of the ten Gag peptide pools tested. These results demonstrated that the Gag DNA vaccine induced specific T cell responses in the DNA priming phase.
Although immunization with DNA plasmids elicited Gag antibody response in the immunized macaques, such antibody titers dropped markedly following gp120 protein boosts (Fig. 2) . In order to determine whether Gag-specific humoral and CMI responses could be boosted following immunization with Gag protein, animals were immunized with a single dose of HIV-1 Gag protein in QS-21 adjuvant on week 58. The immunized animals developed high anti-Gag antibody titers, which dropped with time (data not shown). However, Gag-specific CMI response was not boosted following protein immunization, suggesting that animals were properly primed against Gag antigen for humoral antibody following DNA immunization, but recombinant protein, as an exogenous antigen, was not effective in entering intracellular antigen presentation pathways to boost stronger CMI in gag DNA vaccinated animals (data not shown).
Antibody response during the secondary immunization phase
It is expected that an effective prophylactic vaccine should maintain high-titered antibodies in serum for combating new infections. Alternatively, if decay in antibody titer is observed, additional immunization with the vaccine should boost the titers markedly. Hence, we wanted to determine whether the anti-Env antibody levels would drop following a prolonged rest period and whether such antibody response could be reboosted with the same polyvalent DNA and protein immunizations. Since DNA immunization was necessary to prime both humoral and cellular immune responses in the primary immunization phase, we included a DNA boost in the secondary phase of immunization after a prolonged rest. After a 78-week rest following the second Env protein boost (on week 32), animals were re-immunized with DNA on week 110 and with proteins on week 115 and 132. As shown in Fig. 5 , anti-gp120 titers decreased with time following the second protein boost on week 32. Immunization with a single DNA on week 110 and two protein boosts on weeks 115 and 132 increased anti-gp120 titers comparable to that observed during the primary immunization phase with boosting of antibody responses was more evident following protein immunizations. Given that the antibody titers Fig. 4 . Gag peptide-specific cellular immune responses after the fourth DNA immunization. The numbers of IFN-γ spot-forming cells per 10 6 PBMC were measured by ELISPOT assays. Macaques received NL4-3 Gag DNA vaccine as part of the Env plus Gag DNA vaccine formulation either by a gene gun (animals 961L, 963L, and 969L) or by intradermal injection (animals 971L, 974L, and 975L). Each bar represents the number of spots against one Gag peptide pool. Fig. 5 . Antibody titers to Env protein in macaques immunized with polyvalent DNA and gp120 protein during the secondary immunization phase. Antibody titers in the serum of macaques immunized with DNA by either gene gun (closed symbol) or ID (open symbol) and with gp120 proteins by IM route were assayed by ELISA against Ba-L gp120 protein. Animals were rested from week 32 through week 110 and were subsequently reboosted with DNA and proteins. Serum was collected 2 weeks after each immunization. Antibody titers were calculated as described in Fig. 2 and are presented as mean antibody titer ± SEM from three macaques of either gene gun or ID immunized group. did not increase following DNA administration in the secondary phase of immunization, it is likely that additional priming with DNA may not be necessary in the secondary phase of immunization. These results clearly demonstrate that although antibodies elicited by DNA priming and protein boosts decay as expected, such levels could be brought back to the original level with limited immunizations with Env DNA and protein vaccines.
Protection efficacy after rectal challenge with SHIV-Ba-L Since the immunogens used in this vaccine originated from R5 HIV-1 isolates and such viruses are known to transmit via mucosal surface, these immunized animals were challenged rectally with the chimeric SHIV-Ba-L 3 weeks after the last gp120 protein boost on week 135. SHIV-Ba-L is an R5 isolate and was shown to transmit efficiently via mucosal route without causing any decline in CD4+ T cell counts (Pal et al., 2003) . Plasma RNA loads of each animal over time of both immunized and naïve group are shown in Fig. 6 . All seven animals enrolled in the naïve group were infected following rectal challenge with plasma viremia reaching peak between days 14 and 21 and eventually controlling below detectable level ( Fig. 6A ). Four of the immunized animals (961L, 963L, 974L, and 975L) were shown to have no detectable plasma viremia as evidenced from the RNA load determined by the NASBA assay which has a lower limit sensitivity of 500 copies per milliliter plasma. Two animals (969L and 971L) were infected at peak levels lower than the naïve animals ( Fig. 6B ). This reduction in virus load between the immunized and the naïve controls is significant for peak viremia (P b 0.0012) and for area under the viral RNA peak (P b 0.0023). Area under the viral RNA peak was also significant when gene gun and ID group were compared individually to the naïve group (P b 0.0167). As shown in Fig.  6C , mean peak viremia of the two infected immunized animals was also lower than that of the control group. Virus was isolated from the PBMC of animals with detectable virus load by coculturing with human PBMC and not from animals with undetectable plasma viremia (data not shown). No drop in CD4+ T cell count was noted following challenge in either immunized or control animals (data not shown).
The infectious status of each animal was also confirmed by qualitative PCR detection of SIV proviral DNA from PBMC harvested 120 days following challenge using primers specific to the gag gene. Macaques with no detectable RNA in the plasma were also negative for proviral DNA in PBMC, whereas all the infected animals had detectable SIV proviral DNA (data not shown). As expected, control β-globulin gene expression in the PBMC of all animals tested was comparable (data not shown).
Post-challenge immune response
Animals were monitored after challenge for humoral and cellular immune responses to SHIV-Ba-L (Fig. 7) . As expected, all the immunized animals had high-titered anti-gp120 antibodies on the day of challenge and the antibody titers stabilized 3 weeks following challenge (data not shown). Mean neutralization titers of sera from the protected and the infected animal against SHIV-Ba-L on the day of challenge are shown in Fig. 7A . It is clear that while protected animals had higher neutralizing activity against SHIV-Ba-L compared to infected animals on the day of challenge, the titers in infected Fig. 6 . Plasma viral RNA load in macaques following SHIV-Ba-L challenge. Plasma viral RNA (copies/1 ml) load was determined by NASBA (Romano et al., 2000) . RNA loads of individual animals from naïve (A) and immunized (B) groups are plotted at different days post-challenge. Mean RNA load of seven naïve and two infected macaques of vaccinated groups are plotted with SEM (C). animals increased markedly 3 weeks post-challenge. As expected, sera from the naïve controls had developed weak neutralizing activity only on day 35 post-challenge against SHIV-Ba-L (Fig. 7A) . These immune sera collected on the day of challenge and on week 8 after challenge had weak to no neutralizing activity against multiple heterologous primary HIV-1 isolates (data not shown). These results suggest that although multivalent DNA prime/protein boost vaccine elicited protective immune response in a number of animals against homologous SHIV challenge, such vaccine regimen did not elicit neutralizing antibody response to a broad range of primary HIV-1 isolates.
In order to determine whether CMI response to HIV-1 Env also played a role in controlling SHIV-Ba-L infection in challenged animals, ELISPOT assays were conducted by stimulating PBMC from challenged animals with Ba-L Env peptide pool at different times post-challenge. As shown in Fig.   7B , IFN-γ-specific ELISPOT response was observed in all immunized animals both on the day of challenge and postchallenge. However, no difference was noted between the four protected and two infected animals at any time point. As expected, weak ELISPOT response to Ba-L Env in naïve animals was only observed on day 35 post-challenge (Fig. 7B) . HIV-1 Gag-specific CMI was not measured following challenge since HIV-1 Gag DNA vaccine was not expected to contribute to the protection against a SHIV challenge.
Discussion
Immunogenicity studies conducted here clearly demonstrate that priming of rhesus macaques with DNA encoding env genes from multiple clades of HIV-1 and boosting with the homologous gp120 protein was well tolerated and elicited strong antibody responses in the immunized host. The route of administration was shown to affect antibody responses elicited by the DNA vaccine, as DNA administered by gene gun elicited stronger antibody responses compared to ID route. This finding is consistent with previous studies demonstrating that particle bombardment of DNA restricts the antigen to the epidermal layer and biases the immune response towards Th2 responses (Alvarez et al., 2005; Feltquate et al., 1997; Weiss et al., 2002) . Although higher antibody responses were observed in the gene gun immunized group relative to the ID group, DNA immunization successfully primed humoral responses in all macaques efficiently. Boosting of DNA-primed animals with gp120 proteins enhanced the antibody response markedly to a comparable level in all animals irrespective of the route of DNA administration. Our findings that protein-mediated boosting of humoral responses is not dependent on the route of DNA administration is noteworthy given that gene gun technology may not be available for large-scale human use in the near future, and conventional needle injection may be the method of choice to deliver DNA vaccines, especially in developing countries.
The immunogenicity of polyvalent vaccines may be negatively influenced due to interference among diverse antigens present in the vaccine. Although mixtures of DNA vaccines have been shown to decrease in vivo protein expression thereby reducing immunogenicty of the vaccine (Kjerrstrom et al., 2001; Sedegah et al., 2004) , other studies have demonstrated lack of such interference in multiclade DNA vaccines (Kong et al., 2003; Seaman et al., 2005) . Our results demonstrate that immunization with multivalent env DNA vaccines effectively primed antibody response to each gp120 present in the vaccine. Further, priming of both Gag-specific humoral and cellular immune responses was noted, although gag DNA was administered with four env DNA. This suggests that immune response to Gag antigen was not compromised in the presence of Env antigen.
We demonstrate here that high-titered anti-gp120 antibodies elicited by the DNA prime/protein boost vaccine regimen in rhesus macaques were able to neutralize three homologous HIV-1 isolates efficiently. It is to be noted that the sera harvested after protein boost neutralized SHIV-Ba-L, neutralization of primary Neutralizing antibody titers of sera were expressed as mean neutralizing antibody titers ± SEM from four protected (961L, 963L, 974L, and 975L), two infected (969L and 971L) or from naïve animals. (B) IFN-γ specific ELISPOT assays were conducted with PBMC from four protected, two infected or from naïve macaques collected on the day of challenge and at multiple time points post-challenge in the presence of pooled Ba-L gp120 peptide pools. Results are expressed as mean number of Ba-L Env-specific spot forming cells per 10 6 PBMC ± SEM from four protected or two infected animals.
HIV-1 Ba-L isolate was less efficient especially in FACS-based assay (Fig. 3) . Although SHIV-Ba-L was isolated from the PBMC of an infected macaque, the env gene of this virus was shown to maintain significant homology compared to the parental molecular clone (Pal et al., 2003) . Such homogeneity of the env may account for higher sensitivity of SHIV-Ba-L compared to primary HIV-1 Ba-L , which was propagated exclusively in primary macrophages. We also observed that sera from the majority of the immunized animals were able to neutralize a few heterologous primary HIV-1 isolates mainly from subtype B and even an isolate (DJ263) from subtype A, although Env from clade A was not present in the vaccine. It is possible that the presence of Env antigen from two isolates of subtype B may account for such preferential activity against clade B isolates. Further, neutralization of clade A isolate suggests that protein boost increased the breadth of immune response against other clades not included in the vaccine. Although some of the isolates included in the panel of clade B viruses are known to be neutralization sensitive (MN, SF162, SHIV-Ba-L), progressive increase in the neutralization of these and other isolates (ADA, BA-L) with protein boosts clearly suggest that this vaccine is capable of eliciting neutralizing antibody. Obviously the neutralizing activity elicited by the vaccine is not optimal especially against all primary HIV-1 isolates, and additional efforts are being directed in the selection and design of more potent Env-based immunogens.
Our results demonstrate that the immune response elicited by the multivalent DNA prime/protein boost vaccine was able to protect macaques from rectal challenge with SHIV-Ba-L isolate. This isolate encoding HIV-1 Ba-L env gene was shown to be CCR5 tropic and transmits efficiently via mucosal route without inducing any CD4 decline in the infected macaque (Pal et al., 2003) . It is to be noted that although the virus does not induce a pathogenic outcome in the challenged animals, the transmission characteristics of this R5 SHIV via mucosal route has similarity to other R5 SHIV isolates. First, the plasma viral RNA load observed following rectal challenge with SHIV-Ba-L at the acute stage of infection in naive animals (Fig. 6A) is comparable to that observed with R5 SHIV162P3 (Harouse et al., 1999) . Second, as observed with SHIV-Ba-L, plasma viral RNA load in macaques challenged with SHIV162P3 isolates often drops markedly after the set point and peripheral blood CD4+ T cells are preserved in a majority of the infected animals (data not shown). This polyvalent vaccine formulation was able to confer protection in four out of six animals against SHIV-Ba-L and significantly reduced plasma viremia in the two remaining animals. The conclusion that these animals were negative for SHIV infection was based on three separate experimental results. First, the animals showed no evidence of plasma viremia at any of the time points measured. NASBA assay used for RNA quantitation in plasma has a lower limit sensitivity of 500 copies per milliliter, and these four macaques had RNA loads less than 500 copies per milliliter at all time points. Second, virus could not be isolated by coculturing PBMC from these macaques with human PBMC although such isolation was readily achieved from PBMC of naïve animals and from two infected animals of the immunized group. Third, there was no evidence of proviral DNA in the PBMC of these animals as determined by qualitative PCR assay using gag gene-specific primers, whereas all the infected animals were positive for proviral DNA. While it is possible that the sensitivity of the NASBA assay used here may have precluded detection of lowlevel infection in these animals, given the other lines of evidence of protection in these four animals, we do not believe this to be the case. This efficacy against homologous challenge is significant in light of the fact that the protection was observed against mucosal transmission with a polyvalent vaccine, which elicits broader immune response compared to a monovalent vaccine. However, protection observed here against the homologous challenge precludes complete evaluation of the protective efficacy of the vaccine especially against heterologous challenge. Although the plasma viremia observed during the acute phase of infection following rectal challenge with SHIVBa-L is comparable to other R5 SHIV challenges, there are a few limitations regarding this challenge model. One such limitation is the lack of pathogenesis (i.e., no significant decline in CD4 counts in blood and lack of persistence level of high viremia in the chronic phase of infection) observed with this challenge. To address these limitations and extend our findings, future studies will use heterologous virus challenge with SHIV isolates, which have been shown to be more pathogenic in macaques. Partial efficacy of Env subunit-based vaccine has been noted in other studies against homologous challenge. Although live vector prime and subunit protein boost vaccines did not confer sterilizing protection in rhesus macaques against intravenous challenge with both nonpathogenic and pathogenic homologous SHIV isolates, such vaccines reduced plasma viremia compared to the control group . Further, partial protection from homologous challenge was also noted in macaques immunized with DNA encoding SHIV-SF162ΔV2 Env and such protection was long term (Buckner et al., 2004; Cherpelis et al., 2001a Cherpelis et al., , 2001b .
In order to determine the immune correlates contributing to the efficacy of this vaccine, we assayed neutralizing antibody responses directed to the challenge virus on the day of challenge and up to 5 weeks post-challenge. There was an inverse correlation between the neutralizing activity against the challenge virus and plasma virus load in these animals. Protected animals with no detectable viremia had high neutralizing activity on the day of challenge against the challenge virus, whereas the two infected animals had low neutralizing activity. Interestingly, with time, these two infected animals also developed hightitered neutralizing activity to SHIV-Ba-L and such increase appeared to control plasma viremia rapidly after 3 weeks postchallenge compared to naïve animals. It has recently been demonstrated that CMI response to Env may also play a role in the containment of viral load in challenged animals (Letvin et al., 2004) . Since many of the animals had measurable levels of CMI response to Ba-L Env at the time of challenge, we cannot rule out the possibility that such responses might play a role for containment of viral replication in these animals. It is possible that this challenge outcome was determined by the anti-Env immune responses and not by the SIV Gag antigen since the macaques were immunized with HIV-1 Gag and not with SIV Gag. However, analysis of Gag protein sequence from HIV-1 (pNL4-3) and SIVmac239 revealed 53% homology between the two proteins with partial conservation of a few known CTL epitopes (data not shown). Although not tested, CMI responses elicited by such conserved CTL epitopes for the containment of virus may not be overlooked. Since naïve animals immunized with QS-21 alone were not included in this study as sham controls, it is possible that the CMI responses noted here may, in-part. be due to adjuvant alone. Although such nonspecific CMI responses were not detected throughout this study, the use of adjuvant-immunized animals as sham controls will be included in future studies.
The genetic variation of HIV-1 represents a major obstacle in the development of an effective vaccine against AIDS. Although recently completed phase III clinical trials with recombinant Env proteins have failed to demonstrate protective efficacy against HIV-1 infection (Gilbert et al., 2005) , it is expected that multiple viral proteins from different clades will maximize the breadth and potency of anti-HIV-1 immune response, presumably due to the presentation of multiple antiviral epitopes. A polyvalent Env glycoprotein-based vaccine, primarily with clade B Env of both primary and TCLA strains, elicited a broader antibody response but failed to protect animals from heterologous SHIV challenge (Cho et al., 2001) . The present study demonstrates that polyvalent vaccine comprised of Env from multiple clades and delivered by DNA prime and protein boost is immunogenic in rhesus macaques and elicits neutralizing antibody response to HIV-1. This antibody response was able to confer protection against homologous challenge with an R5 SHIV isolate via mucosal route in several immunized animals. Proper selection of env genes representing specific immunotypes as well as modification of Env proteins may improve the anti-HIV-1 immune response elicited by the vaccines tested in this protocol, and such responses may exhibit benefit as prophylactic vaccine in a population where a number of diverse HIV-1 isolates are present. Hence, this type of vaccine regimen needs to be included in future vaccine development efforts.
Materials and methods
DNA vaccines
The HIV-1 Env and Gag immunogens are listed in Table 2. HIV-1 env genes coding for subtypes B (B715), C, and E were received from Drs. Feng Gao and Beatrice Hahn (University of Alabama, Birmingham), whereas the env gene coding for Ba-L was received from Dr. Marvin Reitz (Institute of Human Virology, Baltimore). The gag gene used in Gag DNA vaccine expressing Gag p55 antigen was derived from the HIV-1 infectious clone pNL4-3 (Adachi et al., 1986 ) (NIH AIDS Research and Reference Reagent Program). The HIV-1 gag gene and gp120 gene inserts coding for the above primary gp120 antigens were first PCR amplified by using the high fidelity PFU polymerase (Strategene, CA) and individually subcloned in the DNA vaccine vector pSW3891. All the DNA vaccines used in the study were constructed using the same vector pSW3891. The pSW3891 was derived from pJW4303 , but the SV40 origin sequence was deleted, and the ampicillin resistance gene was replaced with the Kanamycin resistance gene. The pSW3891 contained cytomegalovirus (CMV) immediate early (IE) promoter and its associated Intron A sequence. The HIV-1 gag or env gp120 inserts were in frame with a tissue plasminogen activator (tPA) leader sequence. The plasmid DNAs for both Env and Gag DNA vaccines were prepared commercially (Althea Inc., CA) and were shown to contain N90% super coil structure with low levels of endotoxin (b20 EU/mg). Each plasmid was shown to be biologically active by measuring the transient expression of either gp120 or p55 Gag protein in 293T cells following transfection (data not shown).
Protein vaccines
Recombinant HIV-1 gp120 proteins were produced in either 293 or CHO cells stably transfected with gp120 expression plasmids. Each codon-optimized gp120 gene was inserted into the expression plasmids in-frame with the tPA signal peptide to facilitate efficient secretion of the gp120 proteins into the media. These plasmids contained the neomycin phosphotransferase II (nptII) and the mouse dihydrofolate reductase (dhfr) genes for selection of stable colonies following transfection. Both 293 and CHO dhfr-cells were transfected with the gp120 expression plasmids using lipofection. Stable cell lines secreting gp120 were selected in the presence of the drug Geneticin (G418 Sulfate). CHO cultures were further selected in the presence of increasing levels of Methotrexate to enhance gp120 production. Both 293 and CHO cultures were cloned by limiting dilution and adapted for growth in serum and proteinfree media, respectively. The gp120 proteins were purified from the conditioned media using Galanthus nivalis lectin agarose. Proteins were formulated with QS-21 adjuvant, which was received from Antigenics Inc. (Woburn, MA). HIV-1 (HXB2) Gag protein (p41) containing domains of both p17 and p24 proteins was expressed as a fusion protein with a poly histidine tag in E. coli using pET23 vector (Novagen, Madison, WI) and purified from the cell lysate by nickel column chromatography and reversed phase HPLC.
Animal studies
Indian rhesus macaques (Macaca mulatta) weighing 4-5 kg were enrolled in the study. Macaques were immunized with (Pal et al., 2003) . Each animal was inoculated with 1 ml of undiluted virus (2000 TCID 50 ) stock rectally since this dose of virus consistently infected naïve animals in separate titration studies.
Binding antibody assay
Serum samples were tested for Env gp120 and Gagspecific antibodies using an enzyme-linked immunoabsorbent assay (ELISA) as described before (Pal et al., 2002) . Briefly, polystyrene plates (Greiner Bio-one, Longwood, FL) were coated with gp120 or Gag p41 protein (50 ng/well) in 100 μl phosphate buffer (pH 7.2) at 4°C overnight. The solution was aspirated, and the wells were washed with wash buffer (PBS containing 0.5% Tween 20) four times, and each well was treated with 200 μl of blocking buffer (water containing 2.5% BSA and 1.25% dry milk) for 1 h at 37°C. After washing with wash buffer, 100 μl of serum serially diluted in Dilsim II (bioMerieux, Inc., Durham, NC) was added to each well and incubated for 1 h at 37°C. Plates were again washed with wash buffer, and each well was incubated for 1 h at 37°C with 100 μl of 1:5000 dilution of goat anti-human HRP labeled IgG (KPL Labs, Gaithersburg, MD) in conjugate buffer (PBS containing 10% normal goat serum, 0.1% Tween 20 and 0.2% BSA). Plates were then thoroughly washed with wash buffer, and each well was reacted with 100 μl of Enhanced K-Blue Substrate (Neogen, Lexington, KY) at room temperature for 30 min. Reaction was terminated by adding 100 μl of 2N H 2 SO 4 to each well, and the optical density was read in an ELISA plate reader at 450 nm. Antibody titers were defined as the highest dilution of immune serum yielding optical density greater than two times the optical density detected with a corresponding dilution of preimmune serum.
Neutralization assays
Different types of neutralization assays were conducted with cell-free virus to measure neutralizing activity of the immune serum. Neutralization assay of SHIV-Ba-L was performed in U373 cells, which express a reporter gene β-galactosidase under HIV-1 LTR promoter. Different dilutions of immune serum were incubated with 200 TCID 50 of SHIV-Ba-L for 60 min at 37°C. Serum-virus mixture was then added to U373 cells coated onto 96-well plates and incubated for 48 h. Cells were thoroughly washed, and fresh medium was added to each well. Expression of β-galactosidase was measured as chemiluminescence output after 96 h to monitor viral infection using Galacto-Start One-
Step Galactosidase Reporter Gene Assay System (Applied Biosystems, Foster City, CA). Neutralization assay based on intracellular p24-Ag (HIV-1 Gag p24 antigen) staining was conducted in 96-well U-bottom culture plates and measured by flow cytometric analysis as previously described (Mascola et al., 2002) . Neutralization of HIV-1MN was assayed in MT2 cells, whereas neutralization of several other primary isolates was also assayed in human PBMC as described before (Crawford et al., 1999) . Additional neutralization assays were conducted in TZMbl cells (NIH AIDS Research and Reference Reagent Program, contributed by John Kappes and Xiaoyun Wu) with pseudo viruses as described elsewhere . Briefly, 200 TCID 50 of virus was incubated with 1:20 dilutions of serum samples in triplicate in a total volume of 150 μl for 1 h at 37°C in 96-well flat-bottom culture plates. Freshly trypsinized cells (10,000 cells in 100 μl of growth medium containing 75 μg/ml DEAE dextran) were added to each well. One set of control wells received cells plus virus (virus control), and another set received cells only (background control). After a 48-h incubation, 100 μl of cells was transferred to 96-well black solid plates for measurements of luminescence using Bright Glo substrate solution as described by the supplier (Promega, Madison, WI). Assay stocks of gp160-pseudotyped viruses were prepared by transfection in 293T cells and titrated in TZM-bl cells.
Neutralization of cell-to-cell transmission was measured by coculturing uninfected CEM cells expressing CCR5 (CEM-CCR5) with either chronically HIV-1 infected CEM-CCR5 or PM1 cells in the presence of the immune serum. Syncytia were scored after 72 h, and the dilutions of serum inhibiting 50% of syncytia were defined as the syncytium blocking titer.
ELISPOT assay
96-well PVDF-bottomed plates (Millipore, Billerica, MA) were pretreated with 70% ethanol and air dried for 15 min. Plates were washed four times with PBS and then coated with 5 μg/ml of mouse anti-human IFNγ capture antibody (BD Pharmingen, San Diego, CA) in PBS and incubated overnight at 4°C. Following incubation, plates were washed five times with complete RPMI media (RPMI1640 supplemented with 10% fetal bovine serum, 2 mM L-glutamine and 100 μg/ml each of penicillin and streptomycin). Rhesus PBMC (2.0 × 10 5 cells/ well) were then added to the wells in 100 μl of complete RPMI and were stimulated with either HIV-1 Env or Gag peptides for 18 h. Care was taken to ensure that final DMSO concentrations did not exceed 0.5%. Following incubation for 18 h at 37°C in a CO 2 incubator, plates were washed five times with PBS containing 0.05% Tween 20. Biotinylated anti-IFNγ (Diapharma, West Chester, OH), diluted with PBS containing 2% fetal bovine serum, 0.05% Tween 20, and 1% BSA, was added to wells at a final concentration of 1 μg/ml. Plates were incubated at 37°C for 2 h and then washed five times with PBS containing 0.5% Tween 20. Avidin-HRP (Vector Laboratories, Burlingame, CA) was diluted in PBS containing 2% FBS, 1% BSA, 0.05% Tween 20, and added to wells at a final dilution of 1:2000. Plates were incubated for 1 h at 37°C. Following incubation, plates were washed five times with wash buffer, and 100 μl of Stable DAB substrate (Research Genetics, Huntsville, AL) was added to each well. Spots were visualized within 3 to 5 min, and the reaction was terminated by washing plates thoroughly with water. Plates were dried overnight, spots were counted using the VWR Vista Vision Stereo Zoom Microscope (VWR, West Chester, PA).
Virological assays to monitor challenge outcome
Animals were bled periodically following challenge, and viral load in plasma was assessed using a more sensitive nucleic acid sequence-based amplification assay (NASBA) to quantitate SIV RNA (Romano et al., 2000) . This assay has a lower limit sensitivity of 500 copies of SIV RNA per milliliter of plasma. To confirm virus transmission, PBMC collected from animals 21 days following virus challenge were subjected to qualitative virus isolation by coculturing with PHA-activated human PBMC (Pal et al., 2002) . In addition, qualitative PCR assays were conducted for the detection of proviral DNA in the PBMC of challenged animals. DNA was isolated from PBMC with Qiagen's QIAmp DNA blood kit (Qiagen, Valencia, CA) using the manufacturer's protocol, and the DNA was amplified with primers specific to the gag gene of SIV using standard conditions of amplification. Amplified product was detected by agarose gel electrophoresis. Amplification of the β-globulin gene served as positive amplification control in each assay.
